NCT05216029Completed
Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma
Study of Efficacy of Oncology Dashboard in Improving Operational Efficiency and Patient Outcomes
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 92 (actual)
- First submitted
- 18 Jan 2022
- Start date
- 1 Oct 2015
- Primary completion date
- 18 Mar 2026
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Sarcoma
- NCT number
- NCT05216029
What you commit to
- Study type: Interventional
- Participants enrolled: 92
- From 1 Oct 2015 to the primary completion date, 18 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non- English-speaking patients and patients with cognitive impairment who cannot complete the questionnaire
Other
- Expected survival of less than 8 weeks
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 4
Who the study is looking for
- Patients with sarcoma on active chemotherapy/targeted therapy
- Patients must have stable to mildly progressive disease or better on baseline assessment
- Baseline measurement and follow-up measurement have to be performed on the same treatment for consistency. If patients with progressive disease are included into the study at baseline, follow-up measurement will be on a different treatment. Invariable, initiation of a new treatment, in the setting of progressive disease, lengthens oncology workflow which would affect the post measurement
- Patients must have been on the same treatment for at least 6 weeks
- Patients must have at least 3 prior imaging studies of the same body part/tracked lesion/area of interest separated by 6 weeks or more between studies
- Patients should be continuing same therapy for the next 6-8 weeks
- Patients must have plan for follow-up with imaging studies at MD Anderson Cancer Center (MDACC) while on therapy
- Patients who are receiving therapy outside of MDACC but having their follow-up imaging at MDACC are eligible
- \>= 18 years of age
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.